Summary:

Over the past decade, there have been significant advances in our understanding of neuroblastoma biology and therapy. Autologous transplantation, historically a cornerstone of consolidation therapy in neuroblastoma, faces many challenges. What is the historical basis for transplantation in neuroblastoma, including the current use of tandem transplants? Are there novel conditioning regimen (including MIBG therapy) that may be incorporated into the transplant process? What is the risk for tumor contamination within our stem cell products, and does the presence of tumor contamination within that stem cell product carry prognostic significance?